AbbVie stock trades 2.05% above Xetra close
Published on 11/20/2026 at 16:05 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWSWhy investors are watching AbbVie
- Piper Sandler raised its price target while retaining an Overweight rating.
- Skyrizi combinations and zumilokibart are central to the long-term immunology outlook.
- Future guidance and pipeline execution remain key valuation drivers.
AbbVie stock traded at 261.85 euros on Lang & Schwarz at 16:01 CET on Friday, November 20, 2026, 2.05 percent above the Xetra close of 256.60 euros on Thursday, November 19. The quote was 1.04 percent above the 259.15-euro price in the latest relevant report published on November 19.
Yahoo Finance reported on November 20 that Piper Sandler had raised its AbbVie price target to USD 349 from USD 303 on November 18 while retaining an Overweight rating. The firm sees scope for further value creation from AbbVie's top-line and EBITDA growth through the end of the decade.
Pipeline supports the revised target
Piper Sandler's view also reflects greater visibility for Skyrizi-containing combination products in inflammatory bowel disease. The firm highlighted the potential for these products to extend the immunology franchise as investors assess longer-term exclusivity and pricing risks.
Zumilokibart is another part of the pipeline discussion, with development in atopic dermatitis and other indications. For investors, the analyst action puts commercial execution and regulatory progress alongside earnings delivery in focus.
Growth must reach expectations
Yahoo Finance said AbbVie reported third-quarter revenue of USD 17.4 billion and raised its 2026 adjusted earnings outlook. Skyrizi and Rinvoq were among the main growth drivers in that period.
The higher target therefore rests on continued growth from newer immunology products while established medicines face pricing and patent-related pressure. Early 2027 guidance will offer the next major test of whether earnings expectations support the revised valuation view.
AbbVie Inc. stock facts
- Company: AbbVie Inc.
- ISIN: US00287Y1091
- Ticker: ABBV
- Home exchange: NYSE
- Trading venue: Lang & Schwarz
- Quote: 261.85 euros at 16:01 CET on November 20, 2026
- Change versus latest report: 1.04 percent above 259.15 euros at 15:33 CET on November 19, 2026
- Xetra close: 256.60 euros on November 19, 2026
- Analyst target: USD 349 from USD 303
- Rating: Overweight
Yahoo Finance's report on Piper Sandler's target also points to future earnings guidance as an important valuation marker.
Broader healthcare valuations remain relevant for investors; see Current market reports.
